Biomarkers such as cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) have been widely studied in order to monitor disease progression or response to therapy in patients post-diagnosed with breast cancer [29–31], however at this point they have unsuccessfully improved patient outcomes. This evidence concerns the gene CEACAM5 and breast carcinoma.